Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 355

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 355
---
 processing hub in Mexico. This hub may be wholly owned by us or developed through a hybrid partnership model, where manage key workflows such as NDA extraction and bioinformatics processing, while the partner laboratory handles sequencing. Establishing this hub will enable us to provide efficient processing services across the region and develop local markets for genomics services, as well as co -developingproducts based on identified local needs and opportunities. To facilitate the creation of the consortium, which we expect to develop within two years, we are engaging with various diagnostic laboratories that are part of the Asociación de Laboratorios de Diagnóstico de Latinoamérica, where one of our founders is also a founding member. Through this network, we are actively seeking partnerships to pilot our products and services, assess market demand, and identify the most promising SKUs to introduce in each market. As of the date of this registration statement on Form F -4, which includes this prospectus, four companies providing diagnostic services have indirectly invested in the Company through the Parent. These companies are Meyer Lab, Laboratorios LABIN, Amadita Laboratorio Clínico, and CIBIC, operating in Paraguay, Costa Rica, the Dominican Republic, and Argentina, respectively. • Integrating AI and genetic data: we obtain data from a diverse set of biological genomic sources (i.e. saliva, stool, blood, and tissue), as well as qualitative sources (clinical and lifestyle), through our commercialization efforts to further improve our products. We are currently developing AI tools to enhance the precision, actionability, and efficiency of our services. Our prospective AI -poweredcapabilities aim at processing diverse biological and qualitative data, such as genomic, clinical and lifestyle information. We further seek to utilize proprietary machine learning algorithms and third -partyLarge Language Models (“LLMs”) that are fine -tunedwith our own data to analyze genomic data, and process and integrate information to present even more precise and actionable results, comprehensive reports, and to automate operational tasks which include the reduction of result turnaround times. Looking ahead, we will implement a phased plan to expand our AI capabilities over the next two to three years. This expansion aims to integrate deeper health insights into our current product offerings, provide 175 more tailored counseling, and improve analytics for prevention and personalized care. We anticipate broader applications, such as advanced research, drug discovery, and clinical trials, to be developed within five years. These initiatives will be supported by investments in proprietary data integration and bioinformatics tools, along with collaboration with internal and external